[Retrospective observational study of the persistence of SARS-CoV-2 infection in patients previously treated with rituximab]. / Estudio observacional retrospectivo de persistencia de infección por SARS-CoV-2 en pacientes tratados previamente con rituximab.

OBJECTIVE: Rituximab-induced immunosuppression could be a risk factor for mortality from COVID-19. The aim of the study was to describe the prevalence of SARS-CoV-2 infection in patients who have received rituximab and its association with a persistent viral infection. METHODS: Retrospective observational study of patients who received rituximab in the 6 months before to the onset of the pandemic. We analyzed the presence of infection and associated them with demographic variables, pathological history related to an increased risk of developing severe COVID-19, the doses of rituximab received, the type of ventilatory support, thromboembolic events, and the treatment received. A descriptive analysis of all the variables was carried out and infected and uninfected patients were compared. RESULTS: We screened a total of 68 patients who had received rituximab (median cumulative dose: 4,161mg (2,611-8,187.5)). 54.4% men, mean age 60.8 years (15.7; 25-87)). C + was confirmed for 22 patients. Of these, 45.5% had high blood pressure, 36.4% Diabetes Mellitus, 31.8% smokers/ex-smoker, 22.7% lung disease, 13.6% heart disease and 4.5% obesity. There were no statistically significant differences between C+ and C-. Only 2 patients developed immunity. For 10 patients (45.5%) did not have a negative CRP until the end of the follow-up. There was no association with cumulative dose of rituximab. The mortality rate was 22.7% in the C+. CONCLUSIONS: We observe that the persistence of the infection leads to a worse evolution of COVID-19. The use of alternatives should be considered during the pandemic, because of patients with decreased B-cell function may have high risk of fatal progression from COVID-19.

Comorbilidad, discapacidad y mortalidad en pacientes pluripatológicos con enfermedad pulmonar obstructiva crónica / Comorbidity, discapacity and mortality in patients with multiple conditions and chronic obstructive pulmonary disease

Objetivo. Estudiar la asociación entre diferentes comorbilidades y condiciones clínicas con la mortalidad en pacientes pluripatológicos (PPP) con enfermedad pulmonar obstructiva crónica (EPOC). Pacientes y métodos Estudio observacional, prospectivo y multicéntrico. Se han incluido pacientes consecutivos con EPOC y criterios de PPP. Se han recogido las variables: edad, sexo, índice de Charlson, comorbilidades, índice de Barthel, índice de Lawton-Brody, test de Pfeiffer, escala de Gijón, nivel de educación, hospitalizaciones en los últimos 3 y 12 meses y supervivencia al cabo de un año. Mediante un análisis univariante y una regresión logística se ha establecido la relación de las variables con la mortalidad. Resultados. Se han incluido 688 PPP con EPOC con edad media 77,9 años. La puntuación media (DE) en el índice de Charlson fue 3,99 (2,07). Las comorbilidades más frecuentes son insuficiencia cardiaca (59%), diabetes (48%), infarto de miocardio (29,4%), insuficiencia renal moderada (22%), enfermedad cerebrovascular (19%), hipertensión arterial (71%), anemia (62%), fibrilación auricular (34%), dislipemia (28%) y obesidad (21%). El 26% tenía dependencia para las actividades básicas de la vida diaria, el 47% precisaba de un cuidador y el 54% tenía riesgo de problema social. Al cabo de un año fallecieron 258 pacientes (37%). El índice de Charlson, la dependencia para las actividades de la vida diaria y la anemia se asocian con una mayor mortalidad y la hipertensión arterial y saber leer y escribir con menor mortalidad. Conclusiones. La comorbilidad y la discapacidad son dos factores pronósticos en los pacientes con EPOC(AU)

Aims. To determine the association between different comorbidities and other clinical conditions with mortality in patients with multiple diseases (PMD) suffering from chronic obstructive pulmonary disease (COPD). Subjects and methods. Patients with COPD and PMD criteria were included in an observational, prospective and multicentrer study. Data on age, gender, Charlson index, Barthel index, Lawton-Brody index, Pfeiffer test, sociofamilial Gijon scale, education level, hospitalizations during the previous 3 and 12 months and survival at one year were collected. The relationship between the variables and mortality were established by means of a univariate analysis and logistic regression model. Results. A total of 688 PMD with COPD and mean age of 77.9 years were included. The mean score one the Charlson index was 3.99 (2.07). The most frequent comorbidities were heart failure (59%), diabetes (48%), myocardial infarction (29%), moderate kidney failure (22%), cerebrovascular disease (19%), hypertension (71%), anemia (62%), atrial fibrillation (34%), dyslipidemia (28%) and obesity (21%). A total of 26% of patients were dependent for activities of daily living, 47% needed a caregiver and 54% were at risk of having social problems. At one year, 258 patients (37%) had died. The Charlson index, dependency for activities of daily living and anemia were associated with mortality and hypertension and capacity for reading and writing were associated with survival(AU)

[Comorbidity, discapacity and mortality in patients with multiple conditions and chronic obstructive pulmonary disease]. / Comorbilidad, discapacidad y mortalidad en pacientes pluripatológicos con enfermedad pulmonar obstructiva crónica.

AIMS: To determine the association between different comorbidities and other clinical conditions with mortality in patients with multiple diseases (PMD) suffering from chronic obstructive pulmonary disease (COPD). SUBJECTS AND METHODS: Patients with COPD and PMD criteria were included in an observational, prospective and multicentrer study. Data on age, gender, Charlson index, Barthel index, Lawton-Brody index, Pfeiffer test, sociofamilial Gijon scale, education level, hospitalizations during the previous 3 and 12 months and survival at one year were collected. The relationship between the variables and mortality were established by means of a univariate analysis and logistic regression model. RESULTS: A total of 688 PMD with COPD and mean age of 77.9 years were included. The mean score one the Charlson index was 3.99 (2.07). The most frequent comorbidities were heart failure (59%), diabetes (48%), myocardial infarction (29%), moderate kidney failure (22%), cerebrovascular disease (19%), hypertension (71%), anemia (62%), atrial fibrillation (34%), dyslipidemia (28%) and obesity (21%). A total of 26% of patients were dependent for activities of daily living, 47% needed a caregiver and 54% were at risk of having social problems. At one year, 258 patients (37%) had died. The Charlson index, dependency for activities of daily living and anemia were associated with mortality and hypertension and capacity for reading and writing were associated with survival. CONCLUSIONS: Comorbidity and discapacity are two prognostic factors in COPD patients.